AbSci Corp (ABSI) News
Filter ABSI News Items
ABSI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ABSI News Highlights
- For ABSI, its 30 day story count is now at 3.
- Over the past 23 days, the trend for ABSI's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DRUG, DEC and WASH are the most mentioned tickers in articles about ABSI.
Latest ABSI News From Around the Web
Below are the latest news stories about ABSCI CORP that investors may wish to consider to help them evaluate ABSI as an investment opportunity.
Absci to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceVANCOUVER, Wash. and NEW YORK, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Absci management is scheduled to present on Thursday, January 11th at 10:30 a.m. Pacific Time (1:30 p.m. Eastern Time). Interested parties may access a live and archived webcast of the presentation on the company’s investor rela |
Absci and PrecisionLife Announce Strategic R&D Partnership to Jointly Develop AI-Enabled Drug PipelineLeading AI biologics and precision medicine innovators will harness technologies to build a diverse portfolio of novel drug treatments With this partnership, Absci achieves 2023 outlook of ten new Active Programs signed for the year VANCOUVER, Wash., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a generative AI drug creation company, and PrecisionLife®, a leading computational biology company driving precision medicine in complex chronic diseases, today announced a collaboration to dev |
Absci (ABSI) Up on AstraZeneca Deal to Design New Cancer TherapyAbsci (ABSI) announces a collaboration agreement with AstraZeneca to develop an AI-designed antibody for an undisclosed oncology target. The stock rises 13%. |
Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology CandidateCollaboration Combines Absci’s AI Antibody Drug Creation Platform with AstraZeneca’s Expertise in Oncology Research and DevelopmentVANCOUVER, Wash., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a leader in generative AI antibody discovery, today announced a collaboration with AstraZeneca, a global biopharmaceutical company, to deliver an AI-designed antibody against an oncology target. This collaboration combines Absci's Integrated Drug Creation™ platform with AstraZeneca' |
AstraZeneca, AI biologics firm Absci tie up on cancer drugAbsci's collaboration with AstraZeneca aims for a zero-shot generative AI model designed to create new and improved antibody therapeutics, the company said. It did not say what kind of cancer they plan to target. Absci applies generative artificial intelligence to design optimal drug candidates based on target affinity, safety, manufacturability and other traits. |
UPDATE 2-AstraZeneca, AI biologics firm Absci tie up on cancer drugAnglo-Swedish drugmaker AstraZeneca has signed a deal worth up to $247 million with U.S. artificial intelligence (AI) biologics firm Absci to design an antibody to fight cancer, Absci said in a statement on Sunday. Absci's collaboration with AstraZeneca aims for a zero-shot generative AI model designed to create new and improved antibody therapeutics, the company said. Absci applies generative artificial intelligence to design optimal drug candidates based on target affinity, safety, manufacturability and other traits. |
Absci to Participate in the Piper Sandler 35th Annual Healthcare ConferenceVANCOUVER, Wash. and NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming Piper Sandler 35th Annual Healthcare Conference in New York, NY. Absci management is scheduled to present on Wednesday, November 29th at 10:50 a.m. Eastern Time (7:50 a.m. Pacific Time). Interested parties may access a live and archived webcast on the company’s investor relations website at: inv |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayWe're starting off Tuesday with a breakdown of all the biggest pre-market stock movers traders need to know about this morning! |
Absci Corp (ABSI) Reports Decrease in Q3 Revenue and Lower Net Loss Year-Over-YearPartnership with Almirall and AI Drug Pipeline Unveiled Amid Financial Adjustments |
Absci Reports Business Updates and Third Quarter 2023 Financial and Operating ResultsEntered into partnership with Almirall to rapidly develop novel treatments for dermatological diseases, for up to $664M in deal value, plus royalties Unveiled AI drug creation pipeline of four wholly-owned assets VANCOUVER, Wash. and NEW YORK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today reported financial and operating results for the quarter ended September 30, 2023. "Our recent achievements further demonstrate the value and p |